420 with CNW – Nearly a Thousand Businesses Sign Letter Asking Congress to Deschedule Marijuana

To mitigate the risks linked with vaping products purchased from the illicit markets, hundreds of leaders in the cannabis industry have signed a the letter for the descheduling of marijuana by Congress.

The letter is to be delivered on Thursday to the House and Senate leadership. The letter argues that the recent increases in injuries and deaths related to vaping are because there are no federal regulations on the sale and use of marijuana because marijuana remains to be a federally controlled substance. The injuries and death are a result of people using adulterated and unregulated weed.

The letter states that any death due to marijuana is one too many in the legal state-regulated marijuana industry. Therefore, to curb the illicit market and prevent future risks, the cannabis industry has to employ tools such as uniformity and good manufacturing practices.

The government should provide consumers with accurate and actionable information on the status of the illegal, untested, and dangerous marijuana products in the markets argued NCIA and its co-signers, who include companies such as Weedmaps, Berkeley Patients Group, SPARC, Leafly, and Vicente Sederberg LLP.

In an interview with a media outlet, the NCIA executive director, Aaron Smith, said that the members of Congress should understand that the failed prohibition policies permitting the continued operation of the unregulated underground market is the leading cause of the increase in the outbreak of vaping related illnesses.

He further stated that the regulation of alcohol at the federal and state level is the reason why there are no alcohol-related illnesses. Therefore, to improve state regulatory systems regarding marijuana and allow for comprehensive research on marijuana as well as limit the illicit market, it is essential for Congress to deschedule and regulate marijuana effectively.

To ensure that the citizens are not exposed to dangerous and untested marijuana products, the letter recommends the adoption of five policies.

First, the removal of cannabis from the Controlled Substances Act and start regulating marijuana in a sensible manner similar to that of alcohol. Moreover, make funds available for investigation of the illnesses by medical specialists in the state.

Secondly, to stop production of vaping equipment installed with thickening agents. The manufacturers should issue a recall of any vaping product that has Vitamin E acetate. Furthermore, licensed retailers should countercheck their stock to make sure they have no products containing Vitamin E acetate.

Thirdly, cannabis consumers should stop using vape cartridges obtained from illegal markets and cease future purchases of any vaping cartridges or products.

NCIA said that the other problem facing the industry is the federal regulations that prohibit legal marijuana businesses from forcing black market operators out of business. NCIA also added that the illicit activities would be disrupted and most probably removed from the markets by legitimate weed businesses if marijuana was removed from Controlled Substances Act.

According to Smith, the NCIA is ready to help the lawmakers and regulators ensure the safety of marijuana consumers. Industry analysts are of the view that companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Marijuana Company of America Inc. (OTCQB: MCOA) long for the day when the federal government finally acts on all the calls that have been made to reschedule marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Provides R&D Program Update

Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today provided an update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria’s patented DehydraTECH(TM) technology. According to the update, most of the investigation and work within the first phase of the project underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) and Lexaria’s majority owned subsidiary Lexaria Nicotine LLC is either complete or significantly underway, with imminent commencement of one remaining aspect. Results have been positive to date and support successful completion of this first phase. “The program between Altria and Lexaria is progressing nicely and is enabling a clearer understanding of the potential of delivering nicotine through oral forms that avoid lung absorption,” Lexaria Bioscience and Lexaria Nicotine CEO Chris Bunka said in the news release. “Lexaria strongly believes that, given the choice, many of the world’s one billion smokers would elect to experience their nicotine in a manner that does not rely on either smoking or vaping, and Lexaria can help enable these alternatives.”

To view the full press releases, visit http://cnw.fm/ZLv7o

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CBDNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://cnw.fm/a3Kr5). An article discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH provides an avenue for safer, less-conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare. . . . ChrgD+ has been available in a limited number of retail stores throughout the Western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life  without having to travel. Limited-time promotional offers and product updates are also available through the site.”

To view the full article, visit http://cnw.fm/rn1CT

About Lexaria Bioscience Corp.

Lexaria is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

420 with CNW – Medical Marijuana Legalization Bill Introduced in Wisconsin

Three legislators in Wisconsin have united to introduce a bill legalizing the use of marijuana for medicinal purposes. The legislators include two Democrats, Erpenbach and Taylor, and Testin who is a Republican.

Sen. Jon Erpenbach, Taylor and Testin in a joint statement on Friday announced that the time has come for the state of Wisconsin to lift the restrictions and legalize the use of marijuana. The bill would create a system that allows patients to be entered into a list through registration and the growers to be issued with a license permitting them to grow cannabis for medical purposes.

In the United States, there are 33 states legally using marijuana either for medical or recreational purposes. Among these are, Michigan and Minnesota. In Colorado and nearly a dozen other states, residents can use marijuana for medical and recreational purposes.

In the statement, Testin said that the government should not decide if marijuana is right for inducing treatment; doctors and patients should be given that mandate to determine if cannabis is right for treating a particular condition.

For the past decade, the Democrats have been trying to pass marijuana legalization bills with no success. However, it is still uncertain whether with the Republican support exemplified by Testin, the bill will be passed into law. Speaker of the Assembly, Robin Vos is open to passing the bill but the Senate Majority Leader, Scott Fitzgerald has openly voiced his opposition.

Tony Evers, the Democratic governor, had proposed legalization of medical marijuana, in the Winsconsin budget, but the provisions were not included in the final budget plan.

Through his spokesman, the governor did not comment on the bill. Moreover, since he is running for Congress in the year 2020 in a Wisconsin district that is traditionally conservative, his stand on the bill is unlikely to change. Supporting the bill would pose a threat for him as it would be a motivating factor for his primary challengers.

The proposed marijuana legalisation bill has the following terms that have to be met by the doctors, patients and the cannabis growers.

Persons qualifying to receive medical marijuana have to be suffering from one of the following ailments; AIDS, cancer, Alzheimer’s, PTSD (post-traumatic stress disorder), traumatic brain injury (TBI), and severe and chronic pain.

Before being registered and joining the list of people to receive medical marijuana treatment, a doctor should diagnose the patient, explain the risk factors as well as the benefits of using medical marijuana.

Patients applying to receive medical marijuana are supposed to pay $250 for registration and $250 in annual fees.

The marijuana registry is not visible to the public and people who are or have been convicted of a drug-related crime are not allowed to join the list.

The Department of Agriculture, Trade and Consumer Protection would set up a licensing system for the growers, if the bill remains as it is. The licensed growers would include persons growing a dozen-plus marijuana plants. Grower would have to pay an initial fee of $250 and an annual fee of $5000. The licensed growers would also be prohibited from growing cannabis for family or personal consumption.

On Friday, Evers tweeted his supports for the bill while pointing to a recent poll by the Marquette University Law School which showed that 83 percent supported the legalization of medical marijuana. In the tweet he wrote that now was the time for physicians to be allowe to prescribe the medication that they felt was best placed to treat their patients.

Analysts believe that the chances of this bill sailing through are too close to call, and they also believe that industry players like IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) would wish that patients have the option of using medical marijuana sooner rather than later.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CBDNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human CBD Study Results Published in Peer Reviewed Clinical Journal

Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced the publication of final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECH(TM) powered TurboCBD(TM); capsules. According to the update results were published in the peer reviewed medical journal, Advances in Therapy, which focuses on clinical medicine and pharmaceutical research and has been published continually since 1984. Lexaria reported several key findings highlighted in the publication, including but not limited to: CBD in-plasma levels with the 90mg dose of TurboCBD were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes; and only the 90 mg dose of TurboCBD was elevated (i.e., greater than the placebo) at 30 minutes and remained elevated at 4 hours.

To view the full press releases, visit http://cnw.fm/oKfH6

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CannabisNewsAudio – Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) Focuses on Innovative Methods of Cannabis Consumption

Related Editorial
A desire to move away from smoking may be fueling growth in the edible cannabis products.

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (SRUTF Profile) is developing new technology to manufacture cannabis edibles and to accurately measure their active ingredients. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has created a bold new technology to make cannabis’ active ingredients more palatable and absorbable. BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) is producing white-label products, giving other brands access to the market. HEXO Corp. (TSX: HEXO) (NYSE: HEXO) is meeting its regulatory needs by acquiring other licensed cannabis producers and processors. Valens GroWorks Corp. (TSX.V: VGW) (OTCQX: VGWCF) has created a large and growing extraction and testing facility.

To hear the CannabisNewsAudio version, visit http://cnw.fm/TDyO4

To view the full editorial, visit http://cnw.fm/rjxQ6

About Sproutly Canada, Inc.

Sproutly is a vertically integrated cannabis products company, powered by proprietary technology and licensed to cultivate and manufacture cannabis derived products under the Cannabis Act. Utilizing the proprietary APP Technology, the company is able to produce Infuz­2O, ­the first naturally water-soluble cannabinoids in water solutions, and Bio-Natural Oil, a natural strain-specific cannabis oil. Sproutly’s indoor cultivation and processing facility is strategically located in Greater Toronto Area. The facility is designed to produce high-quality cannabis and house the initial APP Technology extraction operations. The company’s mission is to advance the cannabis beverage and edibles market and become a leader in the category with its breakthrough products, in-house brand portfolio and partnerships with leading established consumer product brands. For more information, visit the company’s website at www.Sproutly.ca.

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://cnw.fm/SRUTF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Former FDA Boss Hints Marijuana Legalization Is Necessary for Public Health Reasons

The former head of the FDA has said that the conflict between the federal and state marijuana laws has created regulatory gaps which have given chance to tainted or substandard products to enter the market, resulting in the fatal lung injuries that have been reported recently. He hinted that federal action could put an end to this problem.

In a series of tweets, Scott Gottlieb said that the permissive marijuana laws of different U.S. states cause him a lot of worry since they give adults unfettered access to recreational marijuana and yet there are no federal regulations to oversee the production and manufacture of those marijuana products.

In tweets over the weekend, Dr. Gottlieb admitted that illicit vape cartridges, including those that may contain CBD and THC, seem to be behind the spate of lung problems that have so far killed five people and injured hundreds more across the country.

Experts are of the view that those vape cartridges may have contained ingredients not sanctioned for use in vape products (vitamin E acetate, for example) and those ingredients become deadly when they are inhaled.

In a TV appearance, the former FDA commissioner said that states legalize recreational marijuana when they don’t have the capacity to regulate the industry properly, while the federal government which has this needed capacity remains aloof since marijuana is a controlled substance. And when problems arise, states blame the federal government for those problems.

Gottlieb hinted that there is a need for the federal government to rethink its position on marijuana so that it can be possible for legitimate entities that wish to conduct research on the substance to do so.

Without saying marijuana should be federally legalized, Gottlieb’s statement about the need for federal oversight suggests as much because the FDA can only oversee an industry that is legal under federal law.

He also said that under the current legal regime, the FDA may be unable to regulate any vape pens that aren’t intended to be used by the tobacco industry. Making the necessary change would require congressional action, he added.

It appears as though the country is at the same point that it was decades ago just before the prohibition of alcohol ended. At that time, people died after consuming tainted alcohol sold on the black market, and a decision was made to legalize alcohol so that the industry could be legalized. Could the injuries and fatalities attributed to illegal vape cartridges be likely to result in the federal legalization of marijuana?

Analysts aren’t sure that industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Marijuana Company of America (OTCQB: MCOAD) can answer that question in the affirmative.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Technological Innovation Pushes Bounds of Edible Cannabis Market

CannabisNewsWire Editorial Coverage: A desire to move away from smoking may be fueling growth in the edible cannabis products.

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (SRUTF Profile) is developing new technology to manufacture cannabis edibles and to accurately measure their active ingredients. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has created a bold new technology to make cannabis’ active ingredients more palatable and absorbable. BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) is producing white-label products, giving other brands access to the market. HEXO Corp. (TSX: HEXO) (NYSE: HEXO) is meeting its regulatory needs by acquiring other licensed cannabis producers and processors. Valens GroWorks Corp. (TSX.V: VGW) (OTCQX: VGWCF) has created a large and growing extraction and testing facility.

  • Cannabis in food and drink offers both health and social advantages over smoking.
  • The market’s growth depends upon meeting the standards of regulators.
  • Market growth is driving innovation not just in the production of edible cannabis but also in the technology to measure contents.

To view an infographic of this editorial, click here.

Expanding the Bounds of Cannabis

As the legal boundaries of the North American cannabis industry expand, businesses are looking for ways to make the most of their products and reach the widest possible market. This quest has led to a growing shift in focus away from smoking, which is accompanied by significant health concerns and social challenges. Instead, companies are increasingly focused on alternatives such as edible cannabis products.

The growing demand presents challenges. One of the most obvious is developing the technology to effectively extract the active ingredients in cannabis and incorporate them into foods, drinks, vaping oils and other products. In addition, meeting regulatory standards is also a factor, as authorities move to set standards for a newly legalized industry. Meeting such standards means improving control over products, which in turn means improving measurement systems. And that means developing the technology to do the measuring.

The Advantages of Edible Cannabis

Edibles are quickly becoming an important focus for the cannabis market. Some companies are offering edibles, including beverages, as part of a wider product line, creating cannabis-infused drinks alongside wider beverage lines or more diverse cannabis products. Other companies have narrowed their focus to either cannabis edibles or cannabis-infused drinks. For Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G), the focus is on supplying water-soluble cannabis solutions and bionatural oils to be used in the beverages and consumables market.

The shift toward edibles is a direct response to the decrease in smoking. Cannabis legalization has arrived just as tobacco smoking is seeing a steep decline. Both the percentage of people who smoke and the number of cigarettes they consume each day are going down. Many people who are interested in cannabis, whether for medical or recreational reasons, don’t want to take up smoking. If the cannabis industry is to grow, it appears the most effective way may be to find other ways to reach these potential consumers.

Beverages may be one of the most promising ways to replace smoking as the leading form of cannabis consumption; this trend should provide growing business opportunities for companies such as Sproutly. Cannabis-infused beverages allow consumers to choose between alcohol and cannabis on a night out, with users of each able to enjoy the same social setting together.

The downside of this choice is that ingested cannabis typically takes longer to kick in than either alcohol or smoking, disrupting the social dynamic. Sproutly is working to solve this problem with its innovative Infuz2O technology, which provides faster delivery of the active ingredients in ingested cannabis. For both medical users looking for fast relief and recreational users looking to keep pace with their companions, it’s a potentially valuable step.

Cannabis Regulation and Measurement

Cannabis edibles don’t automatically become legal just because cannabis itself has. For example, a delay was written into Canada’s legalization legislation to give time to prepare regulations for ingestible cannabis products such as those Sproutly supports.

These regulations, like those around smokable cannabis, are created with good reason. Governments need to be able to establish standards for recreational drugs to minimize the risk of harm both to consumers and to others who may be affected by those consuming the products.

One form of regulation that appears certain to make its way from alcohol to cannabis is the need to measure and state the strength of consumer products. Two decades of development mean that the methods for these measurements are fairly well established for smokable cannabis, but ingestible cannabis products raise new challenges — ones that Sproutly subsidiary Infusion Biosciences Inc. is addressing.

The methods currently used for the detection and quantitation of cannabinoids were designed for isolated oils. That means they are unable to accurately and reliably measure cannabinoid contents in finished edible and beverage products, which are significantly more complicated. But under the leadership of Sproutly’s chief science officer, Dr. Arup Sen, Infusion Biosciences has developed analytical methods that measure the cannabinoid molecules in water-soluble and oil preparations created using Sproutly’s APP technology. This development marks a significant step toward accurately testing and labeling the content of cannabis ingestibles.

“The ability to test for cannabinoids in water formulations has been unreliable for cannabis beverages globally due to the existing testing standards and practices,” said Sen. “With ever-increasing food-safety standards that need to be met for cannabis beverage and edible products, the completion of our research and the Developed Analytics are significant milestones in the commercialization of APP Technology; this is another step forward towards reliable and accurate testing for ingestible cannabis products.”

Innovating on All Levels

To successfully develop the market for ingestibles, cannabis companies need to be innovating on every level, from the extraction of active ingredients to their measurement, to the recipes for active foods and drinks. Even the way that cannabis is marketed is going to change as its place in people’s lives changes.

Although it’s unlikely that any company will attack this from every angle, it’s a good sign for the market that so many are taking on multiple interlinked issues at once. This is visible in Sproutly’s approach, with the creation of new technology to both create and measure ingestibles.

Infuz2O is the centerpiece of Sproutly’s work. A water-soluble cannabis liquid that moves away from the need for emulsification or encapsulation, Infuz2O allows the delivery of a precisely measured dose of active ingredients from cannabis in an odorless and easy-to-handle form. The effects of the cannabis are felt within five minutes and wear off within 90 minutes, bringing the experience closer to that of alcohol. This delivery method could make it easier to manage for consumers who are new to cannabis or who want to consume their drinks alongside alcohol drinkers, both important pieces for the beverage market.

By developing Infuz2O alongside its testing technology, Sproutly has given itself a way to test the reliability of its product as well as a product to test the measurements on. The move appears to be both a logical and efficient strategy.

Beyond Weed

Cannabis is moving beyond its old image, where “weed” was a fitting label for something that spread where it wasn’t permitted — something primitively grown and furtively consumed. A plethora of companies are now working to develop sophisticated products for a more sophisticated — and legal — market.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is another innovator in the field of delivery methods. The company’s DehydraTECH(TM) technology uses fatty acids to make cannabinoids both more palatable and easier for the body to absorb. This increases the efficiency of cannabis products as well as removing a challenge to the flavor of ingestibles. Like Sproutly, LXRP is working in close cooperation with the authorities to improve the measurement and understanding of cannabinoids through groundbreaking research with the National Research Council of Canada.

BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) is innovating within the industry by importing a business model that has seen little use in cannabis — white-label products. BevCanna researches, packages and produces cannabis-infused beverages to appear under the branding of other companies. The approach keeps the company itself out of the public eye while allowing its clients easy access to this new market without having to develop extensive in-house expertise.

Licensing is an essential part of the cannabis regulatory process. Consequently, companies are moving to acquire more licenses to produce and sell cannabinoids. Some are doing this primarily through their own applications, but others, such as HEXO Corp. (TSX: HEXO) (NYSE: HEXO), have been using acquisitions to build up its businesses. A medical cannabis provider that entered the recreational market last year, HEXO has acquired Newstrike, the parent company of Up Cannabis Inc., a licensed producer and distributor. This acquisition should give HEXO a bigger footprint within the profitable Canadian cannabis market, where unmet demand continues to offer great profit potential.

As a growing number of farmers start cultivating cannabis, somebody needs to provide the extraction and testing services to turn the crops into ingredients for ingestibles. Valens GroWorks Corp. (TSX.V: VGW) (OTCQX: VGWCF) provides extraction and testing services. The company uses a variety of extraction methods to obtain the active ingredients from cannabis crops, producing extracts ideally suited for the products they will be used in. This summer, Valens announced that its extraction capacity had reached 425,000 kg per year, with plans to reach more than a million kilograms.

As the cannabis market shifts towards edible products, extraction and testing work, along with the innovative technology driving it, may become a linchpin of the cannabis economy.

For more information on Sproutly Canada, visit Sproutly Canada Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Findings from Master Collaborative Research Agreement

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced the successful completion of its master collaborative research agreement with the National Research Council of Canada (“NRC”) focused on technical aspects of DehydraTECH(TM)’s drug-delivery processes (http://cnw.fm/gt79T). An article further discussing the company reads, “Lexaria also noted that the National Research Council of Canada study discovered the remarkable stability of DehydraTECH technology, even under highly acidic conditions. ‘Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage,’ the news release states. ‘Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats, and Lexaria’s technology is now proven capable of doing so.’”

To view the full article, visit http://cnw.fm/l6Qac

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Study Announced to Investigate Effect of Medical Marijuana on Driver Performance

The Australian government has given a pharmaceutical company permission to study how medical marijuana affects the driving performance of patients.

As the acceptance of medical cannabis increases around the world, concerns have been raised regarding the potential effects of this medicine on road safety. Currently, many jurisdictions in Australia have laws banning patients who take medical marijuana from driving. These bans are premised on fears that the substance could impair the drivers.

The driving restrictions imposed on drivers, as well as the complex bureaucracy that patients must negotiate before they can be enrolled on the medical cannabis program, have limited the rate at which the medical cannabis program is embraced by people in Australia.

In fact, there have been reports of patients who are advised to try medical marijuana to manage their conditions and they decline because they aren’t willing to forego their liberty to drive in exchange for using medical marijuana.

The cannabinoid known to cause a “high” is THC, and medical marijuana products contain it in varying degrees. However, CBD is the most commonly used cannabinoid in medical marijuana products and it doesn’t make users high. That notwithstanding, it isn’t clear whether CBD can impair one’s ability to drive even if it isn’t euphoric.

That is the question that the makers of CannEpil, a medical cannabis product that contains a 20:1 ratio of CBD and THC, want to answer during this trial. This medicine was developed to treat epilepsy that is unresponsive to existing drugs.

This medication is currently available in the UK and Australia in the category of “investigational medicines.” This classification is given to drugs that have not yet been approved by regulators and are still being studied.

The trial will be conducted as a collaboration between MGC Pharmaceuticals (the makers of the drug), the University of Melbourne, and the Swinburne University of Technology. The study will also be used by the European Medicines Agency (EMA) and Australia’s Therapeutic Goods Administration (ATA) as a source of safety data about the drug.

During the trail, 30 patients will be divided into two groups. One group will receive a placebo while the other group will take CannEpil. The test subjects will then be subjected to driving performance tests using a hi-tech driving simulator provided by the University of Swinburne. The tests are expected to be conducted over a 14-day period.

Analysts believe that industry players like IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will be looking forward to the results of this trial since it could open a serious discussion about some of the myths associated with medical marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com